Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Hex

Hex is an enolase inhibitor and antimalarial agent with Ki values of 74.4 nM and 269.4 nM for ENO2 and ENO1, respectively. Hex is a NfENO and TbENO inhibitor with IC50s value of 0.14 μM and 2.1 μM, respectively. Hex has antimalarial activity against Plasmodium falciparum 3D7, Naegleria fowleri trophozoites and Plasmodium berghei ANKA strain. Hex has anti-tumor effects against intracranial tumors[1][2][3][4][5][6][7][8].

Product Specifications

CAS Number

[2004714-32-1]

UNSPSC

12352005

Target

Enolase; Parasite

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/hex.html

Purity

99.96

Solubility

DMSO : 140 mg/mL (ultrasonic)

Smiles

OP(O)(C1C(N(O)CCC1)=O)=O

Molecular Formula

C5H10NO5P

Molecular Weight

195.11

References & Citations

[1]BOARD OF REGENTS, et al. Enolase inhibitors and methods of treatment there with. WO2016145113A1|[2]Lin YH, et al. An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nat Metab. 2020 Dec;2 (12) :1413-1426. |[3]Milanes JE, et al. Enolase inhibitors as therapeutic leads for Naegleria fowleri infection. PLoS Pathog. 2024 Aug 1;20 (8) :e1012412.|[4]Roster CP, et al. Enolase Inhibitors as Early Lead Therapeutics against Trypanosoma brucei. Pathogens. 2023 Oct 28;12 (11) :1290.|[5]Yan VC, et al. Comparative Pharmacology of a Bis-Pivaloyloxymethyl Phosphonate Prodrug Inhibitor of Enolase after Oral and Parenteral Administration. ACS Pharmacol Transl Sci. 2023 Jan 6;6 (2) :245-252. |[6]Lin Y H, et al. Eradication of ENO1-deleted glioblastoma through collateral lethality. BioRxiv, 2018: 331538.|[7]Jezewski A J, et al. Accelerated erythrocyte senescence causes dose-limiting anemia of antimalarial enolase inhibitors. Hematology. American Society of Hematology. Education Program, 2020. |[8]Jezewski AJ, et al. Targeting Host Glycolysis as a Strategy for Antimalarial Development. Front Cell Infect Microbiol. 2021 Sep 16;11:730413.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture and light)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

Rabbit anti-Human immunodeficiency virus type 1 group M subtype B (isolate LW123)(HIV-1) VIF Polyclonal Antibody
MBS7198982 Inquire

Rabbit anti-Human immunodeficiency virus type 1 group M subtype B (isolate LW123)(HIV-1) VIF Polyclonal Antibody

Ask
View Details
Human Leucine-Rich Alpha-2-Glycoprotein (LRG1) ELISA Development Kit
abx378473-01 5x 96 Tests

Human Leucine-Rich Alpha-2-Glycoprotein (LRG1) ELISA Development Kit

Ask
View Details
Human Leucine-Rich Alpha-2-Glycoprotein (LRG1) ELISA Development Kit
abx378473-02 15x 96 Tests

Human Leucine-Rich Alpha-2-Glycoprotein (LRG1) ELISA Development Kit

Ask
View Details
CHD1L Polyclonal Antibody
MBS8568956-01 0.1 mL

CHD1L Polyclonal Antibody

Ask
View Details
CHD1L Polyclonal Antibody
MBS8568956-02 0.1 mL (AF405L)

CHD1L Polyclonal Antibody

Ask
View Details
CHD1L Polyclonal Antibody
MBS8568956-03 0.1 mL (AF405S)

CHD1L Polyclonal Antibody

Ask
View Details